NCT03368339View on ClinicalTrials.gov

Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis

PHASE2CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

December 10, 2017

Primary Completion Date

January 21, 2018

Study Completion Date

January 28, 2018

Conditions
Allergic Conjunctivitis
Interventions
DRUG

PR013 (0.045%)

PR013 topical Ophthalmic Drops (0.045%)

DRUG

PR013 (0.06%)

PR013 topical Ophthalmic Drops (0.06%)

DRUG

Vehicle

Vehicle

Trial Locations (1)

19148

Principal Investigator, Philadelphia

All Listed Sponsors
lead

Realm Therapeutics, Inc.

INDUSTRY

NCT03368339 - Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis | Biotech Hunter | Biotech Hunter